GFAP anticorps

N° du produit ABIN335357

L’anticorps Souris Monoclonal anti-GFAP a été validé pour WB, IHC, IHC (p) et IHC (fro). Il convient pour détecter GFAP dans des échantillons de Humain. Il y a 1 publication disponible.

Aperçu rapide pour GFAP anticorps (ABIN335357)

Antigène: GFAP (Glial Fibrillary Acidic Protein (GFAP))

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp GFAP est non-conjugé

Application: Western Blotting (WB), Immunohistochemistry (IHC), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunohistochemistry (Frozen Sections) (IHC (fro))

Clone: 6F2

Détail du produit anti-GFAP anticorps

Specificité: Human.

Purification: Purified

Immunogène: 6F2 is a mouse monoclonal IgG1 antibody derived by fusion of mouse myeloma cells with spleen cells from a mouse immunized with glial fibrillary acidic protein from human brain.

Isotype: IgG1

Information d'application

Indications d'application: 6F2 reacts exclusively with glial fibrillary acidic protein which is present in astrocytes in the central nervous system and Schwann cells. 6F2 is suitable for immunoblotting and immunohistochemistry on frozen and paraffin-embedded tissues. Optimal antibody dilution should be determined by titration, recommended range is 1:25 - 1:200 for immunohistochemistry with avidin-biotinylated horseradish peroxidase complex (ABC) as detection reagent, and 1:100 - 1:1000 for immunoblotting applications.

Restrictions: For Research Use only

Stockage

Stock: 4 °C

Références pour anticorps anti-GFAP (ABIN335357)

Van Muijen, Ruiter, Warnaar: "Coexpression of intermediate filament polypeptides in human fetal and adult tissues." dans: Laboratory investigation; a journal of technical methods and pathology, Vol. 57, Issue 4, pp. 359-69, (1987) (PubMed).

Détails sur GFAP

Antigène: GFAP (Glial Fibrillary Acidic Protein (GFAP))

Autre désignation: Glial fibrillary acidic protein / GFAP

Sujet: GFAP (55 kD) is selectively located in astrocytes and represents the major constituent of astrocytic intermediate filaments. GFAP expression levels are highly variable during development of the central nervous system. In adults, GFAP levels increase as a result of the proliferation of astrocytes that occurs in a response to a variety of physical, chemical and etiological insults, including Alzheimer€™s disease, epilepsy and multiple sclerosis. In the peripheral nervous system GFAP is expressed by Schwann cells. Upon differentiation, myelin forming Schwann cells down-regulate GFAP, whereas in non-myelin forming Schwann cells GFAP persists into adulthood.